全文获取类型
收费全文 | 3759篇 |
免费 | 243篇 |
国内免费 | 82篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 205篇 |
妇产科学 | 68篇 |
基础医学 | 431篇 |
口腔科学 | 73篇 |
临床医学 | 378篇 |
内科学 | 1064篇 |
皮肤病学 | 83篇 |
神经病学 | 192篇 |
特种医学 | 432篇 |
外科学 | 432篇 |
综合类 | 51篇 |
一般理论 | 1篇 |
预防医学 | 191篇 |
眼科学 | 90篇 |
药学 | 150篇 |
2篇 | |
中国医学 | 2篇 |
肿瘤学 | 232篇 |
出版年
2023年 | 17篇 |
2022年 | 30篇 |
2021年 | 52篇 |
2020年 | 40篇 |
2019年 | 57篇 |
2018年 | 73篇 |
2017年 | 70篇 |
2016年 | 82篇 |
2015年 | 86篇 |
2014年 | 109篇 |
2013年 | 141篇 |
2012年 | 130篇 |
2011年 | 140篇 |
2010年 | 140篇 |
2009年 | 133篇 |
2008年 | 139篇 |
2007年 | 176篇 |
2006年 | 129篇 |
2005年 | 127篇 |
2004年 | 120篇 |
2003年 | 79篇 |
2002年 | 92篇 |
2001年 | 104篇 |
2000年 | 80篇 |
1999年 | 75篇 |
1998年 | 146篇 |
1997年 | 171篇 |
1996年 | 147篇 |
1995年 | 119篇 |
1994年 | 122篇 |
1993年 | 115篇 |
1992年 | 68篇 |
1991年 | 84篇 |
1990年 | 66篇 |
1989年 | 74篇 |
1988年 | 69篇 |
1987年 | 60篇 |
1986年 | 63篇 |
1985年 | 62篇 |
1984年 | 35篇 |
1983年 | 27篇 |
1982年 | 24篇 |
1981年 | 32篇 |
1980年 | 30篇 |
1979年 | 12篇 |
1978年 | 14篇 |
1977年 | 28篇 |
1976年 | 35篇 |
1975年 | 18篇 |
1973年 | 7篇 |
排序方式: 共有4084条查询结果,搜索用时 31 毫秒
1.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献2.
JM Martín† L Calduch† C Monteagudo‡ I Molina† D Ramón† V Alonso† E Jordᆠ《Journal of the European Academy of Dermatology and Venereology》2006,20(4):428-431
Cutaneous plasmacytosis is a rare disorder characterized by a benign proliferation of mature plasma cells that appears as multiple dark-brown to purplish skin lesions, often associated with polyclonal hypergammaglobulinaemia. We present the case of a 55-year-old Caucasian man who suffered from a cutaneous plasmacytosis associated with two different carcinomas. Cutaneous plasmacytosis seems to be a reactive process because most cases reported are not associated with any apparent underlying disease. Nevertheless, because few reported cases were associated with malignancies, screening of additional neoplasms would be justified. 相似文献
3.
4.
Nafarelin controlled release injectable (CRI) releases a decapeptide drug for target one month therapy. Nafarelin, a luteinizing hormone releasing hormone agonistic analogue, is microencapsulated in biodegradable poly(lactide-co-glycolide) microspheres and given by intramuscular injection. Clinical data from a human single dose Phase I clinical study are modelled to develop theoretical multiple dose profiles and theoretical single dose profiles from mixtures of two or three formulations. Single dose injections of nafarelin CRI microspheres (4 mg nafarelin) containing 2, 4, or 7 per cent nafarelin all achieve useful plasma drug levels throughout the target 30 day interval. Therapeutic suppression of testosterone levels was observed in all subjects participating in the phase I clinical study. Highest plasma nafarelin levels are achieved in the 0-10 and 20-35 day post-injection intervals. Theoretical multiple dosing profiles generated from the single dose clinical results show significant oscillations in plasma nafarelin levels depending on the particular dosing interval selected. Thirty or forty day dosing intervals yield significant variability in plasma nafarelin levels at steady state; 15 day dosing intervals show less variability. Therapeutic testosterone suppression was observed in the single dose study, so the nafarelin dose per injection can be reduced in multiple dosing therapies. Theoretical plasma nafarelin profiles from certain mixtures of 2 and 4 per cent nafarelin microspheres or 2 and 7 per cent nafarelin microspheres indicate that a 60 day product could be achieved. In general, all three formulations yield their lowest plasma drug levels during the 10-20 day post-injection interval. Therefore any mixture of these formulations will likewise exhibit low plasma drug levels during this interval. 相似文献
5.
N Scopinaro E Gianetta D Friedman G F Adami E Traverso B Vitale M Castagnola G Semino M Summa V Bachi 《Gastroenterology Clinics of North America》1987,16(3):529-531
Biliopancreatic diversion is a very effective method for weight reduction. In some instances it is too effective and needs to be revised. 相似文献
6.
Angelo M. Carella Sandro Nati Paolo Carlier Daniela Pierluigi Domenico Giordano Angela Congiu Gino Santini Daniele Scarpati Salvina Barra Renzo Corvo Vito Vitale Maria R. Raffo Raffaella Cerri Marco Risso Mauro Spriano Renato Vimercati Ester Pungolino Andrea Bacigalupo Eugenio Damasio 《Leukemia & lymphoma》1991,5(1):43-47
Forty consecutive adult patients under the age of 50 with acute non-lymphoblastic leukemia (ANLL) in first complete remission, underwent autologous bone marrow transplantation (ABMT) between March 1984 and April 1990. The conditioning regimen employed included cyclophosphamide and total body irradiation, followed by the administration of unpurged ABMT. The median time from diagnosis to transplant was 7 months (3-15 months), and the median time from complete remission to ABMT was 4 months (range 3-9 months). Twenty-two (51%) patients remain in complete remission 6-81 months (median 24 months) after ABMT.
The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants. 相似文献
The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants. 相似文献
7.
JM Vilanova J Figueras-Aloy J Roselló G Gómez E Gelpí R Jiménez 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(5):588-592
The aim of this study was to evaluate the cerebral synthesis of eicosanoids in the asphyctic newborn and to investigate the relation between the prostanoid profiles in cerebrospinal fluid (CSF) and the appearance and severity of hypoxic-ischaemic encephalopathy (HIE). Levels of 6-keto-PGF 1-α, TXB2 , PGE2 and PGF2-α in CSF were measured in 40 full term newborns during the first day of life. Thirty of these newborns had birth asphyxia and were divided into three groups: 10 without HIE, 12 with mild HIE and 8 with moderate-severe HIE. They were compared to a control group of 10 non-hypoxic newborns. Determinations of the metabolites in CSF were performed by RIA and expressed as pg/ml (mean ± SD). The CSF TXB2 (thromboxane A2 metabolite) in asphyxiated newborns was always higher than in the control group (28.12 ± 10.6), and related to the severity of HIE ( p = 0:005): without HIE (50.84 ± 16.4; p = 0:02), mild HIE (80.65 ± 12.64; p ± 0:01) and moderate-severe HIE (178.14 ± 20.5; p < 0:01). The CSF 6-keto-PGF 1-α (prostacyclin metabolite) in asphyxiated newborns was always higher than in the control group (80.55 ± 12.56), but indirectly related to the severity of HIE: without HIE (240.95 ± 28.12; p < 0:01), mild HIE (183.65 ± 30.1; p < 0:01) and moderate-severe HIE (140.55 ± 25.12; p < 0:01). In the moderate-severe HIE group, the increase in TXB2 was higher than the rise in 6-keto-PGF 1-α . 相似文献
8.
9.
Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma 总被引:9,自引:3,他引:6
Weisenburger DD; Gordon BG; Vose JM; Bast MA; Chan WC; Greiner TC; Anderson JR; Sanger WG 《Blood》1996,87(9):3860-3868
Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a distinct clinicopathologic entity associated with the t(2;5) (p23;q35). However, the specificity of t(2;5) for ALCL has not been carefully studied. Therefore, we performed a detailed analysis of all cases of ALCL with abnormal cytogenetics results in the Nebraska Lymphoma Study Group registry, as well as all other cases of non-Hodgkin's lymphoma with t(2;5) in the registry. We found the t(2;5) in only five of 10 cases of ALCL, four of whom were young patients. However, we also found the t(2;5) in 11 other cases of nonanaplastic lymphoma, including eight children with typical peripheral T-cell lymphomas of various types. The t(2;5) was also found in three older adults with B-cell lymphomas of various types. Thus, the t(2;5) was not specific for CD30+ ALCL. However, t(2;5) may define a clinicopathologic entity in children and young adults characterized by variable morphologies with a T-cell or indeterminate phenotype, CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent response to therapy, including bone marrow transplantation for relapsed disease. The clinical relevance of the t(2;5) in older patients requires further study. 相似文献
10.